+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Short Bowel Syndrome - Epidemiology Forecast to 2030

  • ID: 5345917
  • Drug Pipelines
  • June 2021
  • Region: Global
  • DelveInsight
This ‘Short Bowel Syndrome (SBS)-Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Short Bowel Syndrome (SBS), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Short Bowel Syndrome (SBS) Disease Understanding

Short bowel syndrome (SBS) is a congenital or acquired condition affecting the small intestine, hallmarked by loss of intestinal absorptive capacity with resultant malabsorption, dehydration, and malnutrition. This is due to the loss of absorptive surface area, as the human intestinal tract requires a massive surface area to absorb nutrients to support a growing and living organism effectively.

SBS is a challenging condition associated with significant morbidity and mortality, reduced quality of life, and high health care costs. In patients with SBS who are receiving long-term home parenteral nutrition (PN), 2-5 years survival rates have been reported to be up to 80% and 70%, respectively. Factors affecting survival with SBS include the anatomy and function of the remaining bowel, the patient's age, the primary disease process, comorbid diseases, the presence of chronic intestinal obstruction, and the experience of the management team.

Most commonly, SBS develops after surgical removal of a portion of the small intestine. This surgery is done to treat different types of intestinal conditions, like being born with a narrowed small intestine, or missing a portion of this part of the digestive system (intestinal atresia), injury to the intestines from physical trauma, sluggish movement within the intestines, cancer or cancer treatment that impacts the intestines, scarring of the intestines due to Crohn's disease, causing obstruction in the digestive tract, and loss of blood flow to the intestines as a result of blood vessel blockage.

The main symptom of SBS is diarrhea - loose, watery stools. Diarrhea can lead to dehydration, malnutrition, and weight loss. Dehydration means the body lacks enough fluid and electrolytes - chemicals in salts, including sodium, potassium, and chloride - to work properly. Malnutrition is a condition that develops when the body does not get the right amount of vitamins, minerals, and nutrients it needs to maintain healthy tissues and organ function. Loose stools contain more fluid and electrolytes than solid stools. These problems can be severe and can be life-threatening without proper treatment.

Short Bowel Syndrome (SBS) Epidemiology

The Short Bowel Syndrome (SBS) epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Short Bowel Syndrome (SBS) epidemiology segmented as the Prevalent Cases of Short Bowel Syndrome,Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF), Age-specific Cases of SBS, Gender-specific Cases of SBS, Etiology-specific Cases. The report includes the Prevalent scenario of Short Bowel Syndrome (SBS) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country-wise Short Bowel Syndrome (SBS) Epidemiology

The epidemiology segment also provides the Short Bowel Syndrome (SBS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent population of Short Bowel Syndrome (SBS) Associated in 7MM countries was estimated to be 34,713 cases in 2020 and expected to increase at a CAGR of 0.54% for the study period, i.e., 2018-2030.
  • As per the estimates, United States has the highest prevalent population of Short Bowel Syndrome (SBS) in 7MM.
Among the EU5 countries, France had the highest prevalent population of Short Bowel Syndrome (SBS). On the other hand, Spain had the lowest number of cases, 1,701 cases in 2020.

Scope of the Report
  • Short Bowel Syndrome (SBS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Short Bowel Syndrome (SBS) Epidemiology Report and Model provide an overview of the risk factors and global trends of Short Bowel Syndrome (SBS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Short Bowel Syndrome (SBS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Short Bowel Syndrome (SBS)
  • The report provides the segmentation of the Short Bowel Syndrome (SBS) epidemiology by prevalent Cases of Short Bowel Syndrome (SBS) in 7MM
  • The report provides the segmentation of the Short Bowel Syndrome (SBS) epidemiology by Prevalent Cases of Short Bowel Syndrome,Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF), Age-specific Cases of SBS, Gender-specific Cases of SBS, Etiology-specific Cases in 7MM
Report Highlights
  • 10-year Forecast of Short Bowel Syndrome (SBS) epidemiology
  • 7MM Coverage
  • Prevalent Cases of Short Bowel Syndrome
  • Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF)
  • Age-specific Cases of SBS
  • Gender-specific Cases of SBS
  • Etiology-specific Cases
KOL Views

The publisher interviews KOLs, and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM concerning the patient population about Short Bowel Syndrome (SBS)?
  • What are the key findings of Short Bowel Syndrome (SBS) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2030)?
  • What would be the total number of patients with Short Bowel Syndrome (SBS) across the 7MM during the forecast period (2021-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021-2030)?
  • What are the disease risk, burden, and unmet needs of Short Bowel Syndrome (SBS)?
  • What are the currently available treatments for Short Bowel Syndrome (SBS)?
Reasons to Buy

The Short Bowel Syndrome (SBS) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Short Bowel Syndrome (SBS) market
  • Quantify patient populations in the global Short Bowel Syndrome (SBS) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Short Bowel Syndrome (SBS) therapeutics in each of the markets covered
  • Understand the magnitude of Short Bowel Syndrome (SBS) population by its prevalent cases
  • Understand the magnitude of Short Bowel Syndrome (SBS) population by its clinical manifestation specific cases
  • The Short Bowel Syndrome (SBS) epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Short Bowel Syndrome (SBS) Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2018-2030
Note: Product cover images may vary from those shown
1. Key Insights

2. Report Introduction

3. Short bowel syndrome Market Overview at a Glance
3.1. Market Share (%) Distribution of Short bowel syndrome in 2018
3.2. Market Share (%) Distribution of Short bowel syndrome in 2030

4. Executive Summary of Short Bowel Syndrome (SBS)

5. Disease Background and Overview
5.1. Introduction
5.2. Causes
5.3. Symptoms
5.4. Clinical Features and Effect of Malabsorption
5.5. Complications of SBS
5.6. Diagnosis
5.7. Clinical Presentation of Infants with SBS

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. 7MM Total Prevalent Patient Population of Short Bowel Syndrome

7. Epidemiology of Short Bowel Syndrome
7.1. The United States
7.1.1. Prevalent Cases of Short Bowel Syndrome in the United States
7.1.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF) in the United States
7.1.3. Age-specific Cases of SBS in the United States
7.1.4. Gender-specific Cases of SBS in the United States
7.1.5. Etiology-specific Cases in the United States
7.2. EU5
7.3. Germany
7.3.1. Prevalent Cases of Short Bowel Syndrome in Germany
7.3.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF) in Germany
7.3.3. Age-specific Cases of SBS in Germany
7.3.4. Gender-specific Cases of SBS in Germany
7.3.5. Etiology-specific Cases in Germany
7.4. France
7.4.1. Prevalent Cases of Short Bowel Syndrome in France
7.4.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF) in France
7.4.3. Age-specific Cases of SBS in France
7.4.4. Gender-specific Cases of SBS in France
7.4.5. Etiology-specific Cases in France
7.5. Italy
7.5.1. Prevalent Cases of Short Bowel Syndrome in Italy
7.5.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF) in Italy
7.5.3. Age-specific Cases of SBS in Italy
7.5.4. Gender-specific Cases of SBS in Italy
7.5.5. Etiology-specific Cases in Italy
7.6. Spain
7.6.1. Prevalent Cases of Short Bowel Syndrome in Spain
7.6.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF) in Spain
7.6.3. Age-specific Cases of SBS in Spain
7.6.4. Gender-specific Cases of SBS in Spain
7.6.5. Etiology-specific Cases in Spain
7.7. UK
7.7.1. Prevalent Cases of Short Bowel Syndrome in UK
7.7.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF) in UK
7.7.3. Age-specific Cases of SBS in UK
7.7.4. Gender-specific Cases of SBS in UK
7.7.5. Etiology-specific Cases in UK
7.8. Japan
7.8.1. Prevalent Cases of Short Bowel Syndrome in Japan
7.8.2. Prevalent Cases of Short Bowel Syndrome-Intestinal Failure (SBS-IF) in Japan
7.8.3. Age-specific Cases of SBS in Japan
7.8.4. Gender-specific Cases of SBS in Japan
7.8.5. Etiology-specific Cases in Japan

8. Organizations contributing towards Short Bowel Syndrome

9. Patient Journey

10. Case Reports

11. Treatment of Short Bowel Syndrome

12. Management of short bowel syndrome

13. Pharmacological interventions in SBS

14. Surgical management of SBS

15. Appendix
15.1. Bibliography
15.2. Report Methodology

16. Publisher Capabilities

17. Disclaimer

18. About the Publisher
Note: Product cover images may vary from those shown
Adroll
adroll